Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 288

1.

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.

Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, Lombardo I, Hilt DC.

Neuropsychopharmacology. 2015 Jun 19. doi: 10.1038/npp.2015.176. [Epub ahead of print]

PMID:
26089183
2.

Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.

Kelly DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Gold JM, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman SM, Russ JC, Keefe RS, Osing J, Hubzin L, August S, Walker TM, Buchanan RW.

J Clin Psychopharmacol. 2015 Aug;35(4):374-81. doi: 10.1097/JCP.0000000000000345.

PMID:
26082974
3.

Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.

Iwata Y, Nakajima S, Suzuki T, Keefe RS, Plitman E, Chung JK, Caravaggio F, Mimura M, Graff-Guerrero A, Uchida H.

Mol Psychiatry. 2015 Jun 16. doi: 10.1038/mp.2015.68. [Epub ahead of print] Review.

PMID:
26077694
4.

Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.

Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, Dvergsten C, Segreti AC, Beaver JS, Toler SM, Jett JE, Dunbar GC.

Schizophr Bull. 2015 Jun 12. pii: sbv072. [Epub ahead of print]

PMID:
26071208
5.

Validity and reliability of the Brazilian Portuguese version of the BACS (Brief Assessment of Cognition in Schizophrenia).

Araújo GE, Resende CB, Cardoso AC, Teixeira AL, Keefe RS, Salgado JV.

Clinics (Sao Paulo). 2015 Apr;70(4):278-82. doi: 10.6061/clinics/2015(04)10.

6.

Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extend beyond deficits predicted by generalized neuropsychological impairment.

Kristian Hill S, Buchholz A, Amsbaugh H, Reilly JL, Rubin LH, Gold JM, Keefe RS, Pearlson GD, Keshavan MS, Tamminga CA, Sweeney JA.

Schizophr Res. 2015 Aug;166(1-3):310-5. doi: 10.1016/j.schres.2015.05.018. Epub 2015 May 23.

PMID:
26008884
7.

Methods for delivering and evaluating the efficacy of cognitive enhancement.

Harvey PD, Keefe RS.

Handb Exp Pharmacol. 2015;228:5-25. doi: 10.1007/978-3-319-16522-6_1.

PMID:
25977078
8.

Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB).

McCleery A, Green MF, Hellemann GS, Baade LE, Gold JM, Keefe RS, Kern RS, Mesholam-Gately RI, Seidman LJ, Subotnik KL, Ventura J, Nuechterlein KH.

Psychol Med. 2015 Sep;45(12):2657-66. doi: 10.1017/S0033291715000641. Epub 2015 Apr 28.

PMID:
25916421
9.

Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS).

Lim J, Rekhi G, Rapisarda A, Lam M, Kraus M, Keefe RS, Lee J.

Schizophr Res. 2015 May;164(1-3):8-14. doi: 10.1016/j.schres.2015.03.007. Epub 2015 Mar 25.

PMID:
25818728
10.

Lack of Evidence for Regional Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings From the Longitudinal Youth at Risk Study.

Klauser P, Zhou J, Lim JK, Poh JS, Zheng H, Tng HY, Krishnan R, Lee J, Keefe RS, Adcock RA, Wood SJ, Fornito A, Chee MW.

Schizophr Bull. 2015 Mar 4. pii: sbv012. [Epub ahead of print]

PMID:
25745033
11.

A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.

Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian MA.

Schizophr Res. 2015 May;164(1-3):136-42. doi: 10.1016/j.schres.2015.01.041. Epub 2015 Feb 24.

PMID:
25728831
12.

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.

Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS.

Neuropsychopharmacology. 2015 Jul;40(8):2025-37. doi: 10.1038/npp.2015.52. Epub 2015 Feb 17.

PMID:
25687662
13.

Reduced white matter integrity and verbal fluency impairment in young adults with bipolar disorder: a diffusion tensor imaging study.

Bauer IE, Ouyang A, Mwangi B, Sanches M, Zunta-Soares GB, Keefe RS, Huang H, Soares JC.

J Psychiatr Res. 2015 Mar;62:115-22. doi: 10.1016/j.jpsychires.2015.01.008. Epub 2015 Feb 7.

PMID:
25684152
14.

Observable Social Cognition--A Rating Scale: an interview-based assessment for schizophrenia.

Healey KM, Combs DR, Gibson CM, Keefe RS, Roberts DL, Penn DL.

Cogn Neuropsychiatry. 2015;20(3):198-221. doi: 10.1080/13546805.2014.999915. Epub 2015 Feb 13.

15.

Evaluation of cognitive function in bipolar disorder using the Brief Assessment of Cognition in Affective Disorders (BAC-A).

Bauer IE, Keefe RS, Sanches M, Suchting R, Green CE, Soares JC.

J Psychiatr Res. 2015 Jan;60:81-6. doi: 10.1016/j.jpsychires.2014.10.002. Epub 2014 Oct 22.

PMID:
25455513
16.

Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit.

Ethridge LE, Soilleux M, Nakonezny PA, Reilly JL, Hill SK, Keefe RS, Gershon ES, Pearlson GD, Tamminga CA, Keshavan MS, Sweeney JA.

Schizophr Res. 2014 Nov;159(2-3):491-8. doi: 10.1016/j.schres.2014.08.025. Epub 2014 Sep 26.

PMID:
25261042
17.

Regressing to Prior Response Preference After Set Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP Study.

Hill SK, Reilly JL, Ragozzino ME, Rubin LH, Bishop JR, Gur RC, Gershon ES, Tamminga CA, Pearlson GD, Keshavan MS, Keefe RS, Sweeney JA.

Schizophr Bull. 2015 Jul;41(4):940-50. doi: 10.1093/schbul/sbu130. Epub 2014 Sep 5.

PMID:
25194139
18.

Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery.

Gray BE, McMahon RP, Green MF, Seidman LJ, Mesholam-Gately RI, Kern RS, Nuechterlein KH, Keefe RS, Gold JM.

Schizophr Res. 2014 Oct;159(1):182-7. doi: 10.1016/j.schres.2014.07.032. Epub 2014 Aug 22.

PMID:
25156338
19.

Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies.

Hufford MR, Davis VG, Hilt D, Dgetluck N, Geffen Y, Loebel A, Haig G, Santarelli L, Keefe RS.

Schizophr Res. 2014 Oct;159(1):205-10. doi: 10.1016/j.schres.2014.07.018. Epub 2014 Aug 6.

PMID:
25108773
20.

Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review.

Keefe RS, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M.

J Clin Psychiatry. 2014 Aug;75(8):864-76. doi: 10.4088/JCP.13r08609. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk